Last reviewed 2026-04-23 · How we verify

R-FM

R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas.

R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas. Used for Indolent B-cell lymphomas, Mantle cell lymphoma.

At a glance

Mechanism of action

R-FM combines the anti-CD20 monoclonal antibody rituximab with the chemotherapy agents fludarabine (a purine analog) and mitoxantrone (an anthracenedione). Rituximab targets CD20 on B cells to enable antibody-dependent cellular cytotoxicity, while the chemotherapy components provide direct cytotoxic activity. This combination approach is designed to improve response rates in indolent and mantle cell lymphomas.

Approved indications

• Indolent B-cell lymphomas
• Mantle cell lymphoma

Common side effects

• Myelosuppression
• Infection
• Infusion reactions
• Nausea/vomiting
• Fatigue

Key clinical trials

• The LungVision Navigational Platform for Preoperative Labeling of Pulmonary Ground Glass Nodules With Fiducial Markers (NA)
• Muscle Architecture and Muscle Strength in Fibromyalgia
• Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics (PHASE1)
• Correlation Between Clinical Measurement Scales for Gross Motor Function
• Risk Factors of Primary Fibromyalgia
• Use of Amplification in Children With Unilateral Hearing Loss (NA)
• Prophylaxis for Aspiration of Gastric Contents. (PHASE4)
• Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.